IS--(BUSINESS WIRE)--Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today that more than 20 data presentations from the company’s growing multiple sclerosis (MS) portfolio will be showcased at the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS/ACTRIMS 2011). Data to be presented will include new results from pivotal Phase III clinical trials of the company’s lead investigational candidates for the treatment of relapsing MS, LemtradaTM (alemtuzumab) and AubagioTM (oral teriflunomide), and will be featured in platform and poster presentations.
